Key StatisticsCurrency:USD
EPS(TTM)
-1.23
P/E(TTM)
-0.94
BVPS
-1.82
P/B
-0.24
Revenue(2024 Q4)
-123.26M
YoY
-66.99%
Net Income(2024 Q4)
17.98M
YoY
131.98%
Gross Margin(TTM)
47.47%
Net Margin(TTM)
-160.63%
ROE(TTM)
--
Debt ratio
185.60%
Dividend Yield(TTM)
--
Payout Ratio
--
Unveiling the company's Dividend Strategy
Profile

Fibrogen, Inc.
A biopharmaceutical company that developing novel therapeutic agents to treat anemia, fibrotic disease, and cancer
Related Sections
- Biotechnology+1.37%
Pharma Tracker
No Upcoming Event
Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company
Revenue BreakdownCurrency:USD
Business
Region
Data source:2024 FY
Total
29.62M
Name
Revenue
Proportion
Development and Other
1.95M
6.58%
Drug Product
27.67M
93.42%
Major shareholders
Fidelity Management & Research
The Vanguard Group
BlackRock
Astellas Pharma
Thomas B. Neff
DividendsCurrency:USD
No Data
Net Income Attributable to Parent
Total Cash Dividends
Payout Ratio
Unveiling the company's Dividend Strategy
Institutional Holdings
Totally
68
institutions reported their ownerships on FGEN
Institutional Holding Ratio
Price
Insider Transactions
Net increase
Net decrease
Price
Executive Profile
Executives
Board
Disclaimer: All data and information presented above are from third-party data sources. They are for reference only and do not constitute any investment advice.
Market Data Risk Disclosure|Privacy Policy